CA2174550A1 - Suspension of loteprednol etabonate - Google Patents

Suspension of loteprednol etabonate

Info

Publication number
CA2174550A1
CA2174550A1 CA002174550A CA2174550A CA2174550A1 CA 2174550 A1 CA2174550 A1 CA 2174550A1 CA 002174550 A CA002174550 A CA 002174550A CA 2174550 A CA2174550 A CA 2174550A CA 2174550 A1 CA2174550 A1 CA 2174550A1
Authority
CA
Canada
Prior art keywords
suspension
loteprednol etabonate
steroid drugs
water
insoluble steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002174550A
Other languages
French (fr)
Other versions
CA2174550C (en
Inventor
Yaacov J. Guy
Doron Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Yaacov J. Guy
Doron Friedman
Pharmos Corporation
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US142,743 priority Critical
Priority to US08/142,743 priority patent/US5540930A/en
Application filed by Yaacov J. Guy, Doron Friedman, Pharmos Corporation, Bausch & Lomb Incorporated filed Critical Yaacov J. Guy
Priority to PCT/US1994/012059 priority patent/WO1995011669A1/en
Publication of CA2174550A1 publication Critical patent/CA2174550A1/en
Application granted granted Critical
Publication of CA2174550C publication Critical patent/CA2174550C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • Y10S514/914Inflammation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion

Abstract

The invention provides novel compositions of matter for delivering water-insoluble steroid drugs suitable for therapeutic use. The invention also provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of 15µm which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.
CA002174550A 1993-10-25 1994-10-21 Suspension of loteprednol etabonate Expired - Lifetime CA2174550C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US142,743 1993-10-25
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment
PCT/US1994/012059 WO1995011669A1 (en) 1993-10-25 1994-10-21 Suspension of loteprednol etabonate

Publications (2)

Publication Number Publication Date
CA2174550A1 true CA2174550A1 (en) 1995-05-04
CA2174550C CA2174550C (en) 2002-10-01

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002174550A Expired - Lifetime CA2174550C (en) 1993-10-25 1994-10-21 Suspension of loteprednol etabonate

Country Status (17)

Country Link
US (2) US5540930A (en)
EP (1) EP0730443B1 (en)
JP (1) JP3570720B2 (en)
KR (1) KR100341497B1 (en)
AT (1) AT217523T (en)
AU (1) AU697617B2 (en)
BR (1) BR9407958A (en)
CA (1) CA2174550C (en)
DE (1) DE69430635T2 (en)
DK (1) DK0730443T3 (en)
ES (1) ES2179851T3 (en)
HU (1) HU227316B1 (en)
IL (1) IL111402A (en)
NZ (1) NZ275749A (en)
PT (1) PT730443E (en)
SG (1) SG48768A1 (en)
WO (1) WO1995011669A1 (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (en) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 Aqueous suspension of loteprednol etabonate
SE9704186D0 (en) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
WO1999037286A1 (en) * 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Fluorometholone suspension eye drops
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
TR200103694T2 (en) * 1999-06-22 2002-04-22 Boehringer Ingelheim International Gmbh Fixed xylometazoline and oxymetazoline solution
FR2796553B1 (en) * 1999-07-22 2001-09-28 Warner Lambert Co SUSPENSION OF TIXOCORTOL PIVALATE, COLLUTORY BASED ON SAME AND PACKAGING CONTAINING SAME
DK1214056T3 (en) 1999-09-24 2004-02-09 Alcon Inc Topical suspension formulations containing ciprofloxacin and dexamethasone
AR026073A1 (en) 1999-10-20 2002-12-26 Nycomed Gmbh PHARMACEUTICAL COMPOSITION AQUATIC CONTAINING CICLESONIDE
EP1142565A4 (en) * 1999-10-20 2004-03-17 Teijin Ltd Aqueous medicinal compositions
CN1376066A (en) * 1999-11-18 2002-10-23 爱尔康公司 Use of H1 antagonist and a safe steroid to treat eye conditions
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EP1282401A2 (en) * 2000-05-15 2003-02-12 PHARMACIA & UPJOHN S.p.A. Stabilized steroidal suspension
US6462033B2 (en) 2000-07-26 2002-10-08 Alcon Universal Ltd. Process for manufacturing compositions containing ciprofloxacin and hydrocortisone
AT424808T (en) * 2000-11-15 2009-03-15 Chandavarkar Mohan A Pharmaceutical compositions with corticosteroides and anti-infectives
WO2002040030A1 (en) * 2000-11-16 2002-05-23 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
DE60208216T2 (en) 2001-09-21 2006-06-29 Alcon Inc. METHOD FOR THE TREATMENT OF MEDIUM EARINFECTIONS
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US7727549B2 (en) * 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
AU2003301263A1 (en) * 2002-10-18 2004-05-04 Joel S. Echols Three layer tear formulation
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
PT1586316E (en) 2003-01-21 2008-05-28 Senju Pharma Co Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2005041980A1 (en) 2003-11-03 2005-05-12 Ivax Corporation Soft steroid compositions for use in dry powder inhalers
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP4820648B2 (en) * 2003-12-02 2011-11-24 千寿製薬株式会社 Loteprednol etabonate aqueous suspension
PE20050941A1 (en) 2003-12-16 2005-11-08 Nycomed Gmbh AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING
DE602005011928D1 (en) 2004-01-20 2009-02-05 Allergan Inc COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, PREFERABLY CONTAINING TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID
EP1713514A2 (en) * 2004-01-28 2006-10-25 The Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
CA2560824A1 (en) * 2004-03-25 2005-10-13 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1773350B1 (en) * 2004-07-12 2013-05-29 Allergan, Inc. Opthalmic compositions for treating ophthalmic conditions
US8653055B2 (en) * 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
DK1906916T3 (en) * 2005-05-10 2009-01-19 Alcon Inc Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a tonicity regulating glycol based agent, use of the composition for the manufacture of a medicament for the treatment of ophthalmic disorders
PT1885336E (en) * 2005-05-10 2009-05-07 Alcon Inc Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
CA2622001A1 (en) * 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
EP1931388A4 (en) * 2005-09-26 2010-12-15 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
AU2006304416B2 (en) 2005-10-18 2013-03-28 Allergan, Inc. Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2013043387A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
CA2647348A1 (en) 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
ZA200808114B (en) * 2006-03-28 2009-12-30 Javelin Pharmaceuticals Inc Formulations of low dose non-steroidal anti-inflammatory drugs and betacyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (en) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride
EP2054031B1 (en) 2006-07-21 2016-04-06 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
DE602007012559D1 (en) * 2006-09-08 2011-03-31 Univ Johns Hopkins H THE TINY
TWI415629B (en) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
WO2008057360A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
US20090023668A1 (en) * 2006-11-02 2009-01-22 Friedlaender Mitchell H Method for treating blepharitis
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN101721714B (en) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 Passive targeting antitumor prodrug of solid tumor and preparation method thereof
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
BR112013026534A2 (en) * 2011-04-22 2016-12-27 Alcon Res Ltd ophthalmic composition with a viscosity enhancing system having two different viscosity enhancing agents
MX352959B (en) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
JP6138904B2 (en) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー Nonlinear multiblock copolymer drug conjugates for delivery of active agents
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
MX2014013315A (en) * 2012-05-03 2015-09-10 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport.
JP6392209B2 (en) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Lipid-based drug carriers for rapid permeation through the mucus lining
CN103565740A (en) * 2012-07-25 2014-02-12 天津金耀集团有限公司 Loteprednol etabonate suspension eye drops
CN103565742A (en) * 2012-07-25 2014-02-12 天津金耀集团有限公司 Fluorometholone eye drops
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN105189462B (en) 2013-02-20 2017-11-10 卡拉制药公司 Therapeutic compound and its purposes
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR20160099084A (en) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. Crystalline forms of therapeutic compounds and uses thereof
EP3216451A4 (en) * 2014-11-07 2018-06-13 Santen Pharmaceutical Co., Ltd. Ophthalmic aqueous composition
CN106279324A (en) * 2015-05-27 2017-01-04 天津金耀集团有限公司 Loteprednol etabonate monohydrate and crystal formation thereof and preparation method
CN106279325A (en) * 2015-05-27 2017-01-04 天津金耀集团有限公司 A kind of Loteprednol etabonate novel crystal forms and preparation method thereof
CN106892952A (en) * 2015-12-21 2017-06-27 天津金耀集团有限公司 A kind of Loteprednol etabonate novel crystal forms and preparation method thereof
CN106892953A (en) * 2015-12-21 2017-06-27 天津金耀集团有限公司 Loteprednol etabonate monohydrate and its crystal formation and preparation method
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPH0524131B2 (en) * 1983-08-12 1993-04-06 Otsuka Pharma Co Ltd
JPH027574B2 (en) * 1984-08-03 1990-02-19 Takeda Yakuhin Kogyo Kk
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (en) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan PHARMACEUTICAL PREPARATION.
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
PT730443E (en) 2002-11-29
DK0730443T3 (en) 2002-09-09
KR100341497B1 (en) 2002-12-05
DE69430635D1 (en) 2002-06-20
US5747061A (en) 1998-05-05
AU697617B2 (en) 1998-10-15
US5540930A (en) 1996-07-30
JP3570720B2 (en) 2004-09-29
AT217523T (en) 2002-06-15
BR9407958A (en) 1996-11-26
HUT74882A (en) 1997-02-28
JPH09504294A (en) 1997-04-28
DK730443T3 (en)
EP0730443B1 (en) 2002-05-15
HU9601081D0 (en) 1996-06-28
EP0730443A4 (en) 1997-11-05
IL111402A (en) 2000-12-06
WO1995011669A1 (en) 1995-05-04
AU7983594A (en) 1995-05-22
NZ275749A (en) 1998-02-26
HU227316B1 (en) 2011-03-28
SG48768A1 (en) 1998-05-18
ES2179851T3 (en) 2003-02-01
IL111402D0 (en) 1994-12-29
DE69430635T2 (en) 2003-01-02
KR960705541A (en) 1996-11-08
CA2174550C (en) 2002-10-01
EP0730443A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
CA2174550A1 (en) Suspension of loteprednol etabonate
CA2171303A1 (en) Active principles and gas containing microparticles
CA2368843A1 (en) Neurotrophic substituted pyrimidines
HU0100136A3 (en) 11-or 17-substituted estratriols, process for their preparation, use of them and pharmaceutical compositions containing the same
AU6194994A (en) Monomeric bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
AU6194894A (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
CA2163706A1 (en) Amino Acid Derivatives of Paclitaxel
AU6194794A (en) Tetrazole derivatives of bile acids, processes for their preparation and the use of these compounds as medicaments
AU3987693A (en) New substituted phenylimidazolidines, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
AU1428588A (en) Aqueous lamellar silicate dispersions, their use as lacquer auxiliaries, and water-dilutable coating compositions containing lamellar silicates
CA2118219A1 (en) Preparations of low molecular weight hyaluronic acid for stimulating bone formation
AU2974295A (en) Pharmaceutical compositions containing estra-1,3,5(10)-triene derivatives
CA2127443A1 (en) Denture Stabilizing Compositions
AU677868B2 (en) New naphthalene derivatives, processes for their preparation and the pharmaceutical compositions which contain them
CA2000763A1 (en) Dispersable formulation
TW223061B (en) 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2h,5h)-acridinedione and pharmaceutical compositions containing same
AU3573793A (en) 3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidine-4-ones pharmaceutical compositions containing the same and the preparation thereof
CA2163218A1 (en) New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
CA2171446A1 (en) Pseudo- and non-peptide bradykinin receptor antagonists
WO1999006388A8 (en) Pharmaceutical compounds isolated from aristolochia taliscana
AU1841795A (en) Naphthylisoquinoline alkaloids, pharmaceutical compositions containing them and their use for the treatment of malaria
CA2263905A1 (en) Chlorofluorocarbon-free mometasone furoate aerosol formulations
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
AU3378393A (en) Process for the preparation of 3-cyano-3,5,5-trimethylcyclohexanone
ZA9608762B (en) Derivatives of acid pyrazoles, their preparation process, their use as medicaments, their new use and the pharmaceutical compositions containing them.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141021